Equities researchers at Robert W. Baird began coverage on shares of Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) in a report released on Thursday, MarketBeat reports. The brokerage set an "outperform" rating and a $50.00 price target on the stock. Robert W. Baird's target price would suggest a potential upside of 37.85% from the stock's current price.
Other equities research analysts have also issued reports about the company. Stifel Nicolaus upped their price target on Spyre Therapeutics from $36.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, March 26th. Wells Fargo & Company raised shares of Spyre Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price objective for the stock from $12.00 to $35.00 in a research report on Friday, March 1st. Eight research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $41.00.
View Our Latest Research Report on Spyre Therapeutics
Spyre Therapeutics Stock Up 7.1 %
Shares of NASDAQ SYRE traded up $2.40 during trading on Thursday, reaching $36.27. The company had a trading volume of 389,590 shares, compared to its average volume of 451,410. The business's 50-day simple moving average is $35.64. Spyre Therapeutics has a twelve month low of $2.66 and a twelve month high of $47.97. The stock has a market capitalization of $1.31 billion, a PE ratio of -0.48 and a beta of 2.93.
Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($2.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by ($1.80). Equities research analysts expect that Spyre Therapeutics will post -2.36 EPS for the current fiscal year.
About Spyre Therapeutics
(
Get Free Report)
Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).
Further Reading
Before you consider Spyre Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spyre Therapeutics wasn't on the list.
While Spyre Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
